Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Average Recommendation of “Hold” by Brokerages

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have been given an average recommendation of “Hold” by the seven analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $62.8333.

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald raised their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Zacks Research cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 4th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $42.92 on Friday. Supernus Pharmaceuticals has a 1-year low of $40.51 and a 1-year high of $59.68. The company has a market capitalization of $2.50 billion, a P/E ratio of -22.35, a PEG ratio of 0.76 and a beta of 0.56. The business has a 50 day moving average price of $45.63 and a 200 day moving average price of $47.72.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The firm had revenue of $219.06 million for the quarter, compared to analysts’ expectations of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The firm’s revenue for the quarter was up 32.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.40 earnings per share. On average, research analysts expect that Supernus Pharmaceuticals will post 1.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio purchased a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth about $25,000. Rockefeller Capital Management L.P. grew its holdings in Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 660 shares during the period. Hantz Financial Services Inc. grew its holdings in Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 458 shares during the period. Global Retirement Partners LLC acquired a new position in Supernus Pharmaceuticals during the second quarter worth approximately $64,000. Finally, Nykredit A S acquired a new position in Supernus Pharmaceuticals during the second quarter worth approximately $110,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) disorders. The company’s portfolio addresses conditions including epilepsy, migraine and attention-deficit/hyperactivity disorder (ADHD), with an emphasis on extended-release and other drug-delivery technologies.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain epilepsy indications and the prevention of migraine headaches.